Business Wire

Bona Releases 2024 Sustainability Report

8.4.2025 08:05:00 CEST | Business Wire | Press Release

Share

Bona, a global, family-owned company that supplies products for installing, renovating, maintaining, and restoring premium floors, has published its 2024 Sustainability Report. The report underscores Bona’s resilience in navigating a year of global challenges while advancing key sustainability initiatives.

"Throughout 2024 Bona remained steadfast and resilient. Our commitment to sustainability has been a core driver of our innovation, helping us progress toward our environmental, social, and governance goals," said Kerstin Lindell, interim CEO and Chair of the Board, Bona. "We are proud to share the progress we’ve made in reducing our environmental impact, improving working conditions, and fostering greater transparency across our operations."

Key Highlights from the 2024 Sustainability Report

  • 41% Reduction in Greenhouse Gas (GHG) Emissions: Bona achieved a significant reduction in GHG emissions (Scope 1 and 2) compared to 2023, driven by renewable energy certificates in North America and ongoing energy efficiency initiatives.
  • Launch of Bona Mega EVO: This innovative wood floor finish with advanced self-crosslinking technology sets a new standard in sustainability, containing less than 3% volatile organic compounds (VOCs).
  • Award-Winning Commitment to Safety: For the fourth consecutive year, Bona received the U.S. EPA Safer Choice Partner of the Year award, recognizing its efforts to produce safer, high-performance chemical products.
  • Global Expansion: Bona reinforced its international presence by acquiring Ezi Floor Products (EFP), a long-term distribution partner in Australia, to strengthen its operations in the APAC region.

Bona’s 2024 efforts were guided by a commitment to align its practices with evolving global regulations, including steps to comply with the EU Corporate Sustainability Reporting Directive (CSRD). Initiatives also included developing global green claims guidelines to ensure transparency and credibility in sustainability communications.

Björn Johansson, Bona’s Global Sustainability Director, reflected on the company’s progress, stating, “Sustainability remains at the heart of Bona’s strategy. From reducing greenhouse gas emissions to continuously working to improve our offerings to benefit customers, all with an aim to reduce our environmental impact in mind.”

With a vision to lead the sustainability transformation of the flooring industry and achieve carbon neutrality by 2040, Bona continues to embed sustainability at every level of its operations. Lindell added, “At Bona, sustainability is not just a goal but an opportunity to innovate and grow responsibly in a challenging global market.”

The Bona Sustainability Report 2024 is available for download here.

About Bona

Bona is a global, family-owned company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona pioneered the industry by offering waterborne hardwood floor finishing and floor care products. Today, Bona prioritizes the environmental impact of its product and innovates high quality systems for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. The head office is in Malmö, Sweden, and the company is represented globally across 90 countries through 17 subsidiaries, 70 distributors, 4 production sites and over 700 employees. For more information visit www.bona.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250407670188/en/

Contacts

Heather Lindemann | Bona Corporate Communications
+1 (303) 923-6694
heather.lindemann@bona.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye